title: [Immunoregulatory effects of PSK on the Th1/Th2 balance and regulatory T-cells in patients with colorectal cancer].
abstract: It is very important for immunotherapy to release Th2-dominated and Treg-dominated immunological conditions in patients with malignant diseases. In the present study, we assessed the population of CD4+IL-10+T-cells and CD4+Foxp3+T-cells in peripheral blood in patients with colorectal cancer using a flow cytometric analysis, and we investigated whether Th2-dominated and Treg-dominated condition could be modulated by PSK. Peripheral blood samples were collected preoperatively from 40 patients with colorectal cancer before and after oral administration of PSK (3 g/day × 1 week). After PSK treatment, CD4+IL-10+T-cell percentages decreased in 63% of patients and CD4+Foxp3+T-cells percentages decreased in 63% of patients. However, no correlation was found between the ratio of CD4+IL-10+T-cell percentages and that of CD4+Foxp3+T-cell percentages after/before PSK treatment. These results suggest that PSK could release Th2-dominated and Treg-dominated immunological condition in patients with colorectal cancer. Further examinations are needed to investigate the after/before percentage ratio of CD4+Foxp3+T-cells can be useful predicting parameters for the selection of responders of PSK.
authors.affiliation: Dept. of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine.
authors.forename: Shigefumi
authors.initials: S
authors.lastname: Yoshino
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Suzuki
authors.forename: Michihisa
authors.initials: M
authors.lastname: Iida
authors.forename: Shin
authors.initials: S
authors.lastname: Yoshida
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Maeda
authors.forename: Kazunari
authors.initials: K
authors.lastname: Maeda
authors.forename: Shoichi
authors.initials: S
authors.lastname: Hazama
authors.forename: Masaaki
authors.initials: M
authors.lastname: Oka
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018791:CD4 Lymphocyte Count; D015179:Colorectal Neoplasms / Q000276:immunology*; D005434:Flow Cytometry; D051858:Forkhead Transcription Factors / Q000097:blood; D006801:Humans; D016753:Interleukin-10 / Q000032:analysis; D008875:Middle Aged; D011509:Proteoglycans / Q000008:administration & dosage / Q000494:pharmacology*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects*; D058408:Th1-Th2 Balance / Q000187:drug effects*
chemical_list: D000276:Adjuvants, Immunologic; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D011509:Proteoglycans; D016753:Interleukin-10; C010770:polysaccharide-K